Pages

Friday, May 11, 2012

'One in six cancers worldwide are caused by infection'


One in six cancers - two million a year globally - are caused by largely treatable or preventable infections, new estimates suggest.
The Lancet Oncology review, which looked at incidence rates for 27 cancers in 184 countries, found four main infections are responsible.
These four - human papillomaviruses, Helicobacter pylori and hepatitis B and C viruses - account for 1.9m cases of cervical, gut and liver cancers.
Most cases are in the developing world.
The team from the International Agency for Research on Cancer in France, part of the World Health Organization, says more efforts are needed to tackle these avoidable cases and recognise cancer as a communicable disease.
'Preventable'
The proportion of cancers related to infection is about three times higher in parts of the developing world, such as east Asia, than in developed countries like the UK - 22.9% versus 7.4%, respectively.
Nearly a third of cases occur in people younger than 50 years.
Among women, cancer of the cervix accounted for about half of the infection-related cancers. In men, more than 80% were liver and gastric cancers.
Drs Catherine de Martel and Martyn Plummer, who led the research, said: "Infections with certain viruses, bacteria, and parasites are some of the biggest and preventable causes of cancer worldwide
"Application of existing public-health methods for infection prevention, such as vaccination, safer injection practice, or antimicrobial treatments, could have a substantial effect on the future burden of cancer worldwide."
Vaccines are available to protect against human papillomavirus (HPV) - which is linked to cancer of the cervix - and hepatitis B virus - an established cause of liver cancer.
And experts know that stomach cancer can be avoided by clearing the bacterial infection H. pylori from the gut using a course of antibiotics.
Commenting on the work, Dr Goodarz Danaei from Harvard School of Public Medicine in Boston, the US, said: "Since effective and relatively low-cost vaccines for HPV and HBV are available, increasing coverage should be a priority for health systems in high-burden countries."
Jessica Harris of Cancer Research UK said: "It's important that authorities worldwide make every effort to reduce the number of infection-related cancers, especially when many of these infections can be prevented. In the UK, infections are thought to be responsible for 3% of cancers, or around 9,700 cases each year.
"Vaccination against HPV, which causes cervical cancer, should go a long way towards reducing rates of this disease in the UK. But it's important that uptake of the vaccination remains high. At a global level, if the vaccine were available in more countries, many thousands more cases could be prevented."



About Dr Kevin Lau

Dr Kevin Lau DC is the founder of Health In Your Hands, a series of tools for Scoliosis prevention and treatment. The set includes his book Your Plan for Natural Scoliosis Prevention and Treatment, a companion Scoliosis Exercises for Prevention and Correction DVD and the innovative new iPhone application ScolioTrack. Dr Kevin Lau is a graduate in Doctor of Chiropractic from RMIT University in Melbourne Australia and Masters in Holistic Nutrition. He is a member of International Society On Scoliosis Orthopaedic and Rehabilitation Treatment (SOSORT), the leading international society on conservative treatment of spinal deformities. In 2006 I was awarded the "Best Health-care Provider Awards" by the largest Newspaper publication in Singapore on October 18 2006 as well as being interviewed on Primetime Channel News Asia as well as other TV and Radio. For more information on Dr Kevin Lau, watch his interviews or get a free sneak peek of his book, go to: http://www.hiyh.info.

One in six cancers - two million a year globally - are caused by largely treatable or preventable infections, new estimates suggest.
The Lancet Oncology review, which looked at incidence rates for 27 cancers in 184 countries, found four main infections are responsible.
These four - human papillomaviruses, Helicobacter pylori and hepatitis B and C viruses - account for 1.9m cases of cervical, gut and liver cancers.
Most cases are in the developing world.
The team from the International Agency for Research on Cancer in France, part of the World Health Organization, says more efforts are needed to tackle these avoidable cases and recognise cancer as a communicable disease.
'Preventable'
The proportion of cancers related to infection is about three times higher in parts of the developing world, such as east Asia, than in developed countries like the UK - 22.9% versus 7.4%, respectively.
Nearly a third of cases occur in people younger than 50 years.
Among women, cancer of the cervix accounted for about half of the infection-related cancers. In men, more than 80% were liver and gastric cancers.
Drs Catherine de Martel and Martyn Plummer, who led the research, said: "Infections with certain viruses, bacteria, and parasites are some of the biggest and preventable causes of cancer worldwide
"Application of existing public-health methods for infection prevention, such as vaccination, safer injection practice, or antimicrobial treatments, could have a substantial effect on the future burden of cancer worldwide."
Vaccines are available to protect against human papillomavirus (HPV) - which is linked to cancer of the cervix - and hepatitis B virus - an established cause of liver cancer.
And experts know that stomach cancer can be avoided by clearing the bacterial infection H. pylori from the gut using a course of antibiotics.
Commenting on the work, Dr Goodarz Danaei from Harvard School of Public Medicine in Boston, the US, said: "Since effective and relatively low-cost vaccines for HPV and HBV are available, increasing coverage should be a priority for health systems in high-burden countries."
Jessica Harris of Cancer Research UK said: "It's important that authorities worldwide make every effort to reduce the number of infection-related cancers, especially when many of these infections can be prevented. In the UK, infections are thought to be responsible for 3% of cancers, or around 9,700 cases each year.
"Vaccination against HPV, which causes cervical cancer, should go a long way towards reducing rates of this disease in the UK. But it's important that uptake of the vaccination remains high. At a global level, if the vaccine were available in more countries, many thousands more cases could be prevented."



About Dr Kevin Lau

Dr Kevin Lau DC is the founder of Health In Your Hands, a series of tools for Scoliosis prevention and treatment. The set includes his book Your Plan for Natural Scoliosis Prevention and Treatment, a companion Scoliosis Exercises for Prevention and Correction DVD and the innovative new iPhone application ScolioTrack. Dr Kevin Lau is a graduate in Doctor of Chiropractic from RMIT University in Melbourne Australia and Masters in Holistic Nutrition. He is a member of International Society On Scoliosis Orthopaedic and Rehabilitation Treatment (SOSORT), the leading international society on conservative treatment of spinal deformities. In 2006 I was awarded the "Best Health-care Provider Awards" by the largest Newspaper publication in Singapore on October 18 2006 as well as being interviewed on Primetime Channel News Asia as well as other TV and Radio. For more information on Dr Kevin Lau, watch his interviews or get a free sneak peek of his book, go to: http://www.hiyh.info.
Read More


Thursday, May 10, 2012

Feline stem cells

Webb TL, Quimby JM, Dow SW. In vitro comparison of feline bone marrow-derived and adipose tissue-derived mesenchymal stem cells. J Feline Med Surg 2012;14:165-168.

Human_bone_marrow_derived_MSCs
Bone marrow derived stem cells
The use of mesenchymal stem cells (MSC) is being evaluated as a treatment option for a number of different diseases. MSC can be derived from a variety of adult tissues, are fairly non-immunogenic, and their immunosuppressive properties may be of benefit in many immune and inflammatory disease processes. In cats, MSC are being proposed for use in chronic inflammatory or degenerative diseases, such as inflammatory bowel disease and osteoarthritis.

MSC are primarily collected from bone marrow (BM) or adipose tissue (AT) and are then enriched and enhanced before transfer into patients. This study looked at the growth properties and phenotype of feline BM-MSC and AT-MSC from four healthy, young donor cats. The results showed that mesenchymal stem cells isolated from AT proliferated significantly faster than BM-MSC. Also, it was noted that BM-MSC and AT-MSC were similar phenotypically. Therefore, MSC derived from adipose tissue may be the preferred choice for clinical applications when the need for rapid and efficient generation of MSC is important. [VT]
This project was partially supported by a grant from Winn.

Related articles: Quimby JM, Webb TL, Gibbons DS, et al. Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg 2011;13:418-426.

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+

Webb TL, Quimby JM, Dow SW. In vitro comparison of feline bone marrow-derived and adipose tissue-derived mesenchymal stem cells. J Feline Med Surg 2012;14:165-168.

Human_bone_marrow_derived_MSCs
Bone marrow derived stem cells
The use of mesenchymal stem cells (MSC) is being evaluated as a treatment option for a number of different diseases. MSC can be derived from a variety of adult tissues, are fairly non-immunogenic, and their immunosuppressive properties may be of benefit in many immune and inflammatory disease processes. In cats, MSC are being proposed for use in chronic inflammatory or degenerative diseases, such as inflammatory bowel disease and osteoarthritis.

MSC are primarily collected from bone marrow (BM) or adipose tissue (AT) and are then enriched and enhanced before transfer into patients. This study looked at the growth properties and phenotype of feline BM-MSC and AT-MSC from four healthy, young donor cats. The results showed that mesenchymal stem cells isolated from AT proliferated significantly faster than BM-MSC. Also, it was noted that BM-MSC and AT-MSC were similar phenotypically. Therefore, MSC derived from adipose tissue may be the preferred choice for clinical applications when the need for rapid and efficient generation of MSC is important. [VT]
This project was partially supported by a grant from Winn.

Related articles: Quimby JM, Webb TL, Gibbons DS, et al. Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg 2011;13:418-426.

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+

Read More


Monday, May 7, 2012

Scoliosis Treatment - New Exercise Solution!





About Dr Kevin Lau

Dr Kevin Lau DC is the founder of Health In Your Hands, a series of tools for Scoliosis prevention and treatment. The set includes his book Your Plan for Natural Scoliosis Prevention and Treatment, a companion Scoliosis Exercises for Prevention and Correction DVD and the innovative new iPhone application ScolioTrack. Dr Kevin Lau is a graduate in Doctor of Chiropractic from RMIT University in Melbourne Australia and Masters in Holistic Nutrition. He is a member of International Society On Scoliosis Orthopaedic and Rehabilitation Treatment (SOSORT), the leading international society on conservative treatment of spinal deformities. In 2006 I was awarded the "Best Health-care Provider Awards" by the largest Newspaper publication in Singapore on October 18 2006 as well as being interviewed on Primetime Channel News Asia as well as other TV and Radio. For more information on Dr Kevin Lau, watch his interviews or get a free sneak peek of his book, go to: http://www.hiyh.info.




About Dr Kevin Lau

Dr Kevin Lau DC is the founder of Health In Your Hands, a series of tools for Scoliosis prevention and treatment. The set includes his book Your Plan for Natural Scoliosis Prevention and Treatment, a companion Scoliosis Exercises for Prevention and Correction DVD and the innovative new iPhone application ScolioTrack. Dr Kevin Lau is a graduate in Doctor of Chiropractic from RMIT University in Melbourne Australia and Masters in Holistic Nutrition. He is a member of International Society On Scoliosis Orthopaedic and Rehabilitation Treatment (SOSORT), the leading international society on conservative treatment of spinal deformities. In 2006 I was awarded the "Best Health-care Provider Awards" by the largest Newspaper publication in Singapore on October 18 2006 as well as being interviewed on Primetime Channel News Asia as well as other TV and Radio. For more information on Dr Kevin Lau, watch his interviews or get a free sneak peek of his book, go to: http://www.hiyh.info.
Read More


Feline oral cancer: new treatment options

Winn grant W11-027
Cetuximab Targeting of Epidermal Growth Factor Receptor in Feline Oral Squamous Cell Carcinoma
Investigators: Stuart Helfand and Krystal Claybrook; Oregon State University

Tired_20-year-old_cat
Elderly cats are most at risk for oral cancer
Feline oral squamous cell carcinoma (FOSCC) is a common and deadly cancer for which there are no truly effective therapies. This study’s long-term aim is to suppress growth of FOSCC by interrupting signaling through the epidermal growth factor receptor (EGFR). EGFR-signaling is a known trigger for cell growth making it a desirable target for therapy. The study considers two strategies of interest that share the same goal of impeding EGFR signaling. One method is to use cetuximab for monoclonal antibody blockade of the receptor. The alternate method is use of tyrosine kinase inhibitor (TKI) blockade of the receptor’s activation site. The impairment of signaling suppresses a number of processes that would otherwise promote malignant behavior. 

Previous study results showed EGFR is expressed by the only cell line of FOSCC available and that cetuximab can bind to FOSCC biopsy tissue. Despite the prior data, this investigator unexpectedly discovered that cetuximab did not bind to the cells. The study then turned to pursuing the alternate approach to block EGFR signaling by examining a TKI drug, gefitinib, on proliferation of this cell line. Results in this instance confirmed the ability to interrupt EGFR signaling in the cell line by using gefitinib, resulting in suppression of the tumor cells. Data has indicated that this approach is effective and may facilitate use of lower drug doses while achieving superior cell killing.

Additional time is needed to confirm the results and validate targeting of gefitinib (and another TKI drug, dasatinib) to EGFR by western blot analysis. [VT]

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+
Winn grant W11-027
Cetuximab Targeting of Epidermal Growth Factor Receptor in Feline Oral Squamous Cell Carcinoma
Investigators: Stuart Helfand and Krystal Claybrook; Oregon State University

Tired_20-year-old_cat
Elderly cats are most at risk for oral cancer
Feline oral squamous cell carcinoma (FOSCC) is a common and deadly cancer for which there are no truly effective therapies. This study’s long-term aim is to suppress growth of FOSCC by interrupting signaling through the epidermal growth factor receptor (EGFR). EGFR-signaling is a known trigger for cell growth making it a desirable target for therapy. The study considers two strategies of interest that share the same goal of impeding EGFR signaling. One method is to use cetuximab for monoclonal antibody blockade of the receptor. The alternate method is use of tyrosine kinase inhibitor (TKI) blockade of the receptor’s activation site. The impairment of signaling suppresses a number of processes that would otherwise promote malignant behavior. 

Previous study results showed EGFR is expressed by the only cell line of FOSCC available and that cetuximab can bind to FOSCC biopsy tissue. Despite the prior data, this investigator unexpectedly discovered that cetuximab did not bind to the cells. The study then turned to pursuing the alternate approach to block EGFR signaling by examining a TKI drug, gefitinib, on proliferation of this cell line. Results in this instance confirmed the ability to interrupt EGFR signaling in the cell line by using gefitinib, resulting in suppression of the tumor cells. Data has indicated that this approach is effective and may facilitate use of lower drug doses while achieving superior cell killing.

Additional time is needed to confirm the results and validate targeting of gefitinib (and another TKI drug, dasatinib) to EGFR by western blot analysis. [VT]

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+
Read More


Friday, May 4, 2012

Parvovirus in cats and dogs

Stucker KM, Pagan I, Cifuente JO, et al. The role of evolutionary intermediates in the host adaptation of canine parvovirus. J Virol 2012;86:1514-1521.

Cats_and_dogCanine parvovirus (CPV-2) emerged in the late 1970’s as a variant of feline panleukopenia virus (FPV). By the early 1980’s, this variant was replaced by new variants that infected both dogs and cats (CPV-2a and -2b). Interestingly, it is now believed that raccoons may have played a role in the evolution of FPV and its adaptation to dogs, and re-adaptation to cats. Through analysis of all of these viruses and variants, the researchers were able to describe the complex sequence of events, involving small changes in the virus were necessary for these changes in host adaptations. Furthermore, they found that these changes had to occur in concert with one another in order for the adaptation to be successful. These findings show how complex this adaptation to new hosts is, and thus why it is not a common occurrence among viruses. [MK]

Related articles: Horiuchi M, Yamaguchi Y, Gojobori T, et al. Differences in the evolutionary pattern of feline panleukopenia virus and canine parvovirus. Virology 1998;249:440-452.

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+
Stucker KM, Pagan I, Cifuente JO, et al. The role of evolutionary intermediates in the host adaptation of canine parvovirus. J Virol 2012;86:1514-1521.

Cats_and_dogCanine parvovirus (CPV-2) emerged in the late 1970’s as a variant of feline panleukopenia virus (FPV). By the early 1980’s, this variant was replaced by new variants that infected both dogs and cats (CPV-2a and -2b). Interestingly, it is now believed that raccoons may have played a role in the evolution of FPV and its adaptation to dogs, and re-adaptation to cats. Through analysis of all of these viruses and variants, the researchers were able to describe the complex sequence of events, involving small changes in the virus were necessary for these changes in host adaptations. Furthermore, they found that these changes had to occur in concert with one another in order for the adaptation to be successful. These findings show how complex this adaptation to new hosts is, and thus why it is not a common occurrence among viruses. [MK]

Related articles: Horiuchi M, Yamaguchi Y, Gojobori T, et al. Differences in the evolutionary pattern of feline panleukopenia virus and canine parvovirus. Virology 1998;249:440-452.

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+
Read More


Wednesday, May 2, 2012

Improving treatment of feline kidney disease

Winn grant W12-039
Administration of pimobendan to cats with chronic kidney disease
Investigators: Mary Anna Labato, Brandi R. Gallagher, John Rush; Tufts University

MP900400715Chronic kidney disease (CKD) is one of the most common reasons geriatric cats present to the veterinarian. CKD is considered irreversible and progressive, and effective treatments are limited. A common co-existing condition seen in feline CKD patients is heart disease. Two of the investigators in this study have administered pimobendan to cats with combined kidney and heart disease. The patients had developed congestive heart failure (CHF) secondary to intravenous fluid administration, a typical standard of care for kidney disease. In some of these patients, addition of pimobendan resulted in a great improvement in kidney values and clinical response. Tolerability and safety of this drug has already been established in cats with heart disease. This will be a pilot study to assess the tolerability of pimobendan in cats with CKD and search for benefits in comparison to the current standard of care. Investigating these observations in a larger study will help establish whether pimobendan could be a novel treatment for cats with CKD. 

This project is available for sponsorship. When you sponsor a project, your name will be added to the list of the project's supporters on our website and in any publications we produce about the project. You will receive exclusive pre-publication reports on the progress of your chosen project as they become available, and a final report at its conclusion.

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+
Winn grant W12-039
Administration of pimobendan to cats with chronic kidney disease
Investigators: Mary Anna Labato, Brandi R. Gallagher, John Rush; Tufts University

MP900400715Chronic kidney disease (CKD) is one of the most common reasons geriatric cats present to the veterinarian. CKD is considered irreversible and progressive, and effective treatments are limited. A common co-existing condition seen in feline CKD patients is heart disease. Two of the investigators in this study have administered pimobendan to cats with combined kidney and heart disease. The patients had developed congestive heart failure (CHF) secondary to intravenous fluid administration, a typical standard of care for kidney disease. In some of these patients, addition of pimobendan resulted in a great improvement in kidney values and clinical response. Tolerability and safety of this drug has already been established in cats with heart disease. This will be a pilot study to assess the tolerability of pimobendan in cats with CKD and search for benefits in comparison to the current standard of care. Investigating these observations in a larger study will help establish whether pimobendan could be a novel treatment for cats with CKD. 

This project is available for sponsorship. When you sponsor a project, your name will be added to the list of the project's supporters on our website and in any publications we produce about the project. You will receive exclusive pre-publication reports on the progress of your chosen project as they become available, and a final report at its conclusion.

More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Read the Cat Health News Weekly
Join us on Google+
Read More


Monday, April 30, 2012

Feline Health Symposium: Diving into the Gene Pool

Registration is now open for the 34th Annual Winn Feline Foundation Feline Health Symposium. This year's event, "Diving into the Gene Pool", will take place on Thursday, June 28, 2012, from 4:00 to 6:00 pm at the Boston Marriott Quincy, in Quincy, MA.

“We are excited to announce that two preeminent feline healthcare researchers will be delivering the program. Leslie Lyons, PhD, University of California, Davis will present ‘The Next Generation of Feline Genetics’ and John Rush, DVM, DACVIM, DACVECC, Tufts University will speak on ‘Feline Cardiomyopathy - More than Genes! New thoughts on Causes, Diagnosis, and Treatment’",stated Dr. Vicki Thayer, Winn Feline Foundation Board President.

Dr. Lyons will speak on recent genetic sequencing of the cat which has led to development of a powerful new genetic resource, the cat 63K DNA array. Dr. Lyons will present examples of recent successes for identification of mutations causing cat traits and diseases. In addition, discussion will cover a new study design to evaluate more challenging traits, such as FIP resistance and susceptibility, and other complex conditions in the cat. While genetic mutations contribute to many forms of hypertrophic cardiomyopathy (HCM) in the cat, these mutations cannot explain all of the manifestations of the disease. Dr. Rush will present information and research relative to diagnostic testing, dietary implications, and new drugs for treatment of feline cardiomyopathy.

All event proceeds will benefit worldwide medical research on feline HCM via Winn’s Ricky Fund, established in 2002 with the specific purpose of raising funds for feline HCM research. 

The registration fee, which includes light snacks with a cash bar, is $25. Reservations are required by June 17, 2012. Detailed information and registration options are available on our website and in the event flyer.

For more information, contact:
Maureen Walsh, Winn Chief Executive Officer
mwalsh@winnfelinehealth.org
Registration is now open for the 34th Annual Winn Feline Foundation Feline Health Symposium. This year's event, "Diving into the Gene Pool", will take place on Thursday, June 28, 2012, from 4:00 to 6:00 pm at the Boston Marriott Quincy, in Quincy, MA.

“We are excited to announce that two preeminent feline healthcare researchers will be delivering the program. Leslie Lyons, PhD, University of California, Davis will present ‘The Next Generation of Feline Genetics’ and John Rush, DVM, DACVIM, DACVECC, Tufts University will speak on ‘Feline Cardiomyopathy - More than Genes! New thoughts on Causes, Diagnosis, and Treatment’",stated Dr. Vicki Thayer, Winn Feline Foundation Board President.

Dr. Lyons will speak on recent genetic sequencing of the cat which has led to development of a powerful new genetic resource, the cat 63K DNA array. Dr. Lyons will present examples of recent successes for identification of mutations causing cat traits and diseases. In addition, discussion will cover a new study design to evaluate more challenging traits, such as FIP resistance and susceptibility, and other complex conditions in the cat. While genetic mutations contribute to many forms of hypertrophic cardiomyopathy (HCM) in the cat, these mutations cannot explain all of the manifestations of the disease. Dr. Rush will present information and research relative to diagnostic testing, dietary implications, and new drugs for treatment of feline cardiomyopathy.

All event proceeds will benefit worldwide medical research on feline HCM via Winn’s Ricky Fund, established in 2002 with the specific purpose of raising funds for feline HCM research. 

The registration fee, which includes light snacks with a cash bar, is $25. Reservations are required by June 17, 2012. Detailed information and registration options are available on our website and in the event flyer.

For more information, contact:
Maureen Walsh, Winn Chief Executive Officer
mwalsh@winnfelinehealth.org
Read More